https://www.breastcancer.org/research-news/varied-results-for-tecentriq-plus-chemo-for-mtnbc
Studies Show Conflicting Results With Tecentriq and Chemotherapy for Metastatic Triple-Negative...
studies show
https://www.roche.com/investors/updates/inv-update-2018-01-19
TECENTRIQ approved in Japan for the treatment of unresectable, advanced or recurrent NSCLC
https://www.roche.com/media/releases/med-cor-2019-03-11
FDA grants Roche's Tecentriq in combination with Abraxane accelerated approval for people with...
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with...
https://www.goodrx.com/compare/tecentriq-vs-tecentriq-hybreza
Tecentriq vs. Tecentriq Hybreza for Lung Cancer: Important Differences and Potential Risks.
Compare Tecentriq and Tecentriq Hybreza side effects, costs and risks for treating Lung Cancer.
lung cancertecentriqvs
https://www.roche.com/media/releases/med-cor-2021-01-12
Roche to present updated data confirming Tecentriq in combination with Avastin substantially...
Tecentriq in combination with Avastin provides the longest overall survival seen in a front-line Phase III study in unresectable hepatocellular carcinoma...
https://www.roche.com/media/releases/med-cor-2018-10-22
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped...
The Phase III IMpower130 study investigating the Tecentriq plus chemotherapy combination demonstrated a significant overall survival (OS) and progression-free...
https://www.roche.com/investors/updates/inv-update-2018-12-07
FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial...
Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous...
https://www.healthdirect.gov.au/medicines/brand/amt,1028131000168108/tecentriq
Tecentriq | healthdirect
On this page about Tecentriq you will find information relating to side effects, age restrictions, food interactions, whether the medicine is available at a...
tecentriqhealthdirect
https://www.medicines.org.uk/emc/product/15037/pil
Tecentriq 1,875 mg solution for injection - Patient Information Leaflet (PIL) - (emc) | 15037
Tecentriq 1,875 mg solution for injection - Patient Information Leaflet (PIL) by Roche Products Limited
patient information leaflet
https://www.vidal.fr/medicaments/gammes/tecentriq-84010.html
TECENTRIQ
tecentriq
https://www.tga.gov.au/news/news-articles/lapse-provisional-registration-tecentriq-atezolizumab-treatment-locally-advanced-or-metastatic-triple-negative-breast-cancer-mtnbc
Lapse of provisional registration for Tecentriq (atezolizumab) for the treatment of locally...
Apr 14, 2026 - Provisional registration of Tecentriq (atezolizumab) for the treatment in mTNBC will lapse on 22 March 2023.
provisional registrationthe treatmentlapsetecentriqatezolizumab
https://www.roche.com/media/releases/med-cor-2019-01-17
FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy...
Basel, 17 January 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company's...
biologics license application
https://www.roche.com/investors/updates/inv-update-2019-03-11
FDA grants Roche's Tecentriq in combination with Abraxane accelerated approval for people with...
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with...
https://www.cancerresearchuk.org/about-cancer/treatment/drugs/atezolizumab
Atezolizumab (Tecentriq) | Cancer information | Cancer Research UK
Atezolizumab is an immunotherapy for bladder, urinary system or non small cell lung cancer (NSCLC). Find out how you have it, possible side effects and other...
cancer informationatezolizumabtecentriqresearchuk